NEW YORK, June 13, 2024 /PRNewswire/ -- Atlantic Coastal Acquisition Corp. II (NASDAQ:ACAB) (the "Company"), a special purpose acquisition company, announced that it had previously received written notification (the "Notice") from the Listing Qualifications Department of The Nasdaq Stock Market ("Nasdaq") on June 3, 2024 that, because the Company had not yet filed its Quarterly Report on Form 10-Q for the three month period ended March 31, 2024 (the "10-Q") with the Securities and Exchange Commission (the "SEC"), the Company was not in compliance with Nasdaq's continued listing requirements under Nasdaq Listing Rule 5250(c)(1). The Notice has no immediate effect on the listing of the Company
WOBURN, Mass. and NEW YORK, Jan. 22, 2024 (GLOBE NEWSWIRE) -- Abpro Corporation ("Abpro"), a biotech company with the mission of improving the lives of mankind facing severe and life-threatening diseases with next-generation antibody therapies, and Atlantic Coastal Acquisition Corp. II (NASDAQ:ACAB), a special purpose acquisition company ("Atlantic Coastal"), today announced the filing of a registration statement on Form S-4 (the "Registration Statement") with the U.S. Securities and Exchange Commission ("SEC") on January 19, 2024, which includes a preliminary proxy statement and prospectus in connection with its proposed business combination. Upon the closing of the proposed business
Abpro is a biotechnology company specializing in the development of next-generation antibody therapies intended to improve the lives of those with life-threatening diseases. The transaction values Abpro at $725 million and will help advance Abpro's drug pipeline to clinical trials. Abpro Corporation ("Abpro"), a biotechnology company with the mission of improving the lives of those facing severe and life-threatening diseases with next-generation antibody therapies, and Atlantic Coastal Acquisition Corp. II (NASDAQ:ACAB), a special purpose acquisition corporation ("Atlantic Costal"), today announced a term sheet to enter into a definitive business combination, which was entered into o
Abpro is a biotechnology company specializing in the development of next-generation antibody therapies intended to improve the lives of those with life-threatening diseases.The transaction values Abpro at $725 million and will help advance Abpro's drug pipeline to clinical trials.Abpro Corporation ("Abpro"), a biotechnology company with the mission of improving the lives of those facing severe and life-threatening diseases with next-generation antibody therapies, and Atlantic Coastal Acquisition Corp. II (NASDAQ:ACAB), a special purpose acquisition corporation ("Atlantic Costal"), today announced a term sheet to enter into a definitive business combination, which was entered into on Septembe
SC 13G/A - Atlantic Coastal Acquisition Corp. II (0001893219) (Subject)
SC 13G/A - Atlantic Coastal Acquisition Corp. II (0001893219) (Subject)
SC 13D - Atlantic Coastal Acquisition Corp. II (0001893219) (Subject)
4 - Atlantic Coastal Acquisition Corp. II (0001893219) (Issuer)
3 - Atlantic Coastal Acquisition Corp. II (0001893219) (Issuer)
4 - Atlantic Coastal Acquisition Corp. II (0001893219) (Issuer)
DEFA14A - Atlantic Coastal Acquisition Corp. II (0001893219) (Filer)
DEFA14A - Atlantic Coastal Acquisition Corp. II (0001893219) (Filer)
DEFA14A - Atlantic Coastal Acquisition Corp. II (0001893219) (Filer)